Business
HeartBeam Announces Closing of Initial Public Offering
SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine
About this update from Heartbeam, Inc.
[{"type":"text","content":" SANTA CLARA, Calif.--(BUSINESS WIRE)--\nHeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, today announced the closing of its underwritten initial public offering of 2,750,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $6.00. The common stock and warrants were issued separately in this offering. The warrants have an exercise price of $6.00 per share and are exercisable for a period of five years after the issuance date. The common stock and warrants are traded on the Nasdaq Capital Market under the ticker symbols “BEAT” and “BEATW,” respectively.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211117005534/en/HeartBeam, Inc. (NASDAQ: BEAT) IPO on the Nasdaq Capital Market (Photo: Business Wire)\nThe net proceeds to HeartBeam from the offering, deducting the underwriting discounts and commissions and offering expenses, amount to $14.9 million.\n\nThe Benchmark Company, LLC acted as sole book-running manager for the offering.\n\nThe securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (Registration No. 333-259358) that was previously filed with the U.S. Securities and Exchange (the \"SEC\") and declared effective on November 10, 2021. This offering was made only by means of a prospectus. Copies of the prospectus can be obtained through the SEC's website at www.sec.gov or from: The Benchmark Company, Attn: Prospectus Department, 150 E. 58th Street, 17th floor, New York, NY 10155 or by calling 212-312-6700 or by emailing [email protected].\n\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\n\nAbout HeartBeam, Inc.\n\nHeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascu...